Peripheral neuropathy Board decisions

The Board remands the claims for service connection for multiple joint arthritis and neuropathy to obtain a clarifying medical opinion regarding their etiology, specifically addressing presumed herbicide agent exposure during active duty.

The Board granted earlier effective dates for the award of service connection for left and right lower extremity neuropathy, but remanded issues related to an increased rating for lumbar strain and a claim for dizziness and vertigo.

The Board remands the claims for service connection for hypertension, ischemic heart disease, and peripheral neuropathy of both hands and feet to obtain additional evidence regarding in-service exposure to herbicide agents.

The Board dismissed the veteran's claims for increased ratings and TDIU due to various conditions, as the issues were remanded under the modernized appeal system.

The Board remands the Veteran's claims for additional development, specifically to obtain an adequate VA medical opinion that addresses the etiology of the Veteran's claimed conditions, with consideration and discussion of relevant evidence.

The Board granted a 40 percent disability rating for sciatic nerve, peripheral neuropathy, left and right lower extremities starting from May 23, 2024, but denied increased ratings in excess of 20 percent for femoral and sciatic nerve conditions prior to that date.

The Board remands the claims for service connection of peripheral neuropathy of the bilateral upper extremities and a higher rating for prostate and bladder cancer with urinary frequency to correct pre-decisional errors.

The appeal for the issues of entitlement to an effective date earlier than December 11, 2015, for the grant of service connection for left upper and lower extremity peripheral neuropathy was withdrawn by the Veteran's representative. The appeals for increased ratings were denied due to insufficient evidence of severe or complete paralysis.

The Board remands the claims for service connection for primary cutaneous B-Cell lymphoma, Non-Hodgkin's disease and other conditions to correct a pre-decisional duty-to-assist error.

The Board remands the claims for an initial disability rating higher than 10 percent for right and left lower extremity peripheral neuropathy associated with Hodgkin's lymphoma due to pre-decisional duty to assist errors.

The Board granted restoration of a 30 percent rating for right upper extremity diabetic peripheral neuropathy, effective from July 6, 2020, and remanded the other claims for further development.

The Board dismissed the Veteran's claims for earlier effective dates for service connection for right ankle disability, lower right extremity neuropathy, and residual right ankle scar.

The Board denied service connection for type II diabetes mellitus and diabetic peripheral neuropathy of the left lower extremity, finding that neither condition was related to the Veteran's active military service.

The Board denied the Veteran's claim for service connection for peripheral neuropathy of the lower extremities, finding that the evidence did not support a link between the condition and his active service.

The Board remands the issue of entitlement to service connection for residuals of COVID-19 infection, including Guillain-Barré Syndrome and chronic inflammatory demyelinating polyneuropathy (CIDP), for further development.

The Board remands the claims for further development to correct a duty to assist error regarding the Veteran's service connection and initial rating claims.

The Board denied the Veteran's appeal for earlier effective dates for service connection of peripheral neuropathy affecting all four extremities, finding no clear and unmistakable error in prior denials and that the earliest possible effective date was June 17, 2018.

The Board dismissed the appeal for service connection of peripheral neuropathy in all extremities due to a prohibited concurrent election.

The Board denied increased ratings for seborrheic dermatitis, diabetes mellitus II, left and right upper extremity peripheral neuropathy, and right lower extremity peripheral neuropathy. However, it granted an initial 40 percent rating for both the right and left lower extremity peripheral neuropathy, as well as a 10 percent rating for hypertension.

The Board granted an effective date of January 15, 2023, for the award of service connection for coronary artery disease (CAD) and a 100 percent rating from that date. The claims for earlier effective dates for right and left upper extremity peripheral neuropathy were denied.